Cowen Inc’s Amicus Therapeutics FOLD Stock Holding History

Cowen Inc’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-35,000	Closed	-$4K	–	489
2019 Q1	$4K	Buy	+35,000	New	+$428K	﹤0.01%	355
2018 Q4	–	Sell	-15,800	Closed	-$8K	–	364
2018 Q3	$8K	Buy	+15,800	New	+$221K	﹤0.01%	467
2017 Q3	–	Sell	-40,000	Closed	-$402K	–	249
2017 Q2	$402K	Buy	40,000 +39,650	+11,329%	+$319K	0.02%	231
2017 Q1	$250K	Buy	+350	New	+$2.21K	0.01%	200

Other funds holding FOLD

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Cowen Inc's FOLD Position: Q1 2019 in Review

Cowen Inc sold out of Amicus Therapeutics (FOLD) in Q1 2019, closing a stake of 12,353 shares — an estimated $151K sold.

Cowen Inc first reported a position in FOLD in Q4 2015 and held it in 7 quarters. The position peaked at $2.22M in Q3 2017. 205 funds tracked by Wall St. Rank hold FOLD as of Q1 2019.

Cowen Inc reported no remaining Amicus Therapeutics position as of Q1 2019 after selling out during the quarter.
Cowen Inc sold 12,353 Amicus Therapeutics shares in Q1 2019, an estimated $151K.
Cowen Inc first reported a position in Amicus Therapeutics in Q4 2015 and held it in 7 quarters.
Cowen Inc's Amicus Therapeutics position peaked at $2.22M in Q3 2017.
205 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2019.

Based on Cowen Inc's 13F filing for Q1 2019, filed 14 May 2019.